⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TNXP News
Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering
globenewswire.com
TNXP
Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
globenewswire.com
TNXP
Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University
globenewswire.com
TNXP
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel
globenewswire.com
TNXP
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations
globenewswire.com
SNGX
AMGN
FOLD
CTOR
TNXP
Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder
globenewswire.com
TNXP
Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment
globenewswire.com
TNXP
Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights
globenewswire.com
TNXP
Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference
globenewswire.com
TNXP
Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection
globenewswire.com
TNXP